Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
Open Access
- 10 June 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Respiratory Research
- Vol. 11 (1), 1-8
- https://doi.org/10.1186/1465-9921-11-73
Abstract
Previous studies indicate that patients with pulmonary arterial hypertension (PAH) carrying a mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene, develop the disease 10 years earlier than non-carriers, and have a more severe hemodynamic compromise at diagnosis. A recent report has suggested that this may only be the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients with truncating mutations. We reviewed data from all patients with PAH considered as idiopathic and patients with a family history of PAH, who underwent genetic counselling in the French PAH network between January, 1st 2004 and April, 1st 2010. We compared clinical, functional, and hemodynamic characteristics between carriers and non-carriers of a BMPR2 mutation, according to gender or BMPR2 mutation type. PAH patients carrying a BMPR2 mutation (n = 115) were significantly younger at diagnosis than non-carriers (n = 267) (35.8 ± 15.4 and 47.5 ± 16.2 respectively, p < 0.0001). The presence of a BMPR2 mutation was associated with a younger age at diagnosis in females (36.4 ± 14.9 in BMPR2 mutation carriers and 47.4 ± 15.8 in non-carriers, p < 0.0001), and males (34.6 ± 16.8 in BMPR2 mutation carriers and 47.8 ± 17.1 in non-carriers, p < 0.0001). BMPR2 mutation carriers had a more severe hemodynamic compromise at diagnosis, but this was not influenced by gender. No differences in survival and time to death or lung transplantation were found in male and female PAH patients carrying a BMPR2 mutation. No differences were observed in clinical outcomes according to the type of BMPR2 mutations (missense, truncating, large rearrangement or splice defect). When compared to non-carriers, BMPR2 mutation carriers from the French PAH network are younger at diagnosis and present with a more severe hemodynamic compromise, irrespective of gender. Moreover, BMPR2 mutation type had no influence on clinical phenotypes in our patient population.Keywords
This publication has 24 references indexed in Scilit:
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertensionRespiratory Research, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in femalesEuropean Respiratory Journal, 2009
- Penetrance of pulmonary arterial hypertension is modulated by the expression of normalBMPR2alleleHuman Mutation, 2009
- Gene expression in BMPR2 mutation carriers with and without evidence of Pulmonary Arterial Hypertension suggests pathways relevant to disease penetranceBMC Medical Genomics, 2008
- Clinical Implications of Determining BMPR2 Mutation Status in a Large Cohort of Children and Adults With Pulmonary Arterial HypertensionThe Journal of Heart and Lung Transplantation, 2008
- Stoichiometric imbalance in the receptor complex contributes to dysfunctional BMPR-II mediated signalling in pulmonary arterial hypertensionHuman Molecular Genetics, 2008
- Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial HypertensionCirculation, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004